SPY312.23+1.71 0.55%
DIA258.42+1.11 0.43%
IXIC10,207.63+53.00 0.52%

Morgan Stanley Maintains Overweight on Rubius Therapeutics, Lowers Price Target to $15

Morgan Stanley maintains Rubius Therapeutics (NASDAQ:RUBY) with a Overweight and lowers the price target from $17 to $15.

Benzinga · -

Morgan Stanley maintains Rubius Therapeutics (NASDAQ:RUBY) with a Overweight and lowers the price target from $17 to $15.